Published on: Jan 22, 2018 at Morningstar

Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium

By : Morningstar

At ASCO this weekend, new data was shared from a clinical trial of margetuximab and pembrolizumab for patients with advanced gastric cancer, where researchers are “… encouraged by the tolerability and anti-tumor activity of this novel, chemotherapy-free regimen…”

Read More
SHARE